Search

Your search keyword '"Lin, Guo-He"' showing total 38 results
Start Over Author "Lin, Guo-He"
38 results on '"Lin, Guo-He"'

33. Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection

Author

Chen, Jian-Lin, primary, Lao, Xiang-Ming, additional, Lin, Xiao-Jun, additional, Xu, Li, additional, Cui, Bo-Kang, additional, Wang, Jun, additional, Lin, Guo-He, additional, Shuang, Ze-Yu, additional, Mao, Yi-Ze, additional, Huang, Xin, additional, Yun, Jing-Ping, additional, Jin, Jie-Tian, additional, and Li, Sheng-Ping, additional

Published
2016
Full Text
View/download PDF

35. Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection.

Author

Jian-Lin Chen, Xiang-Ming Lao, Xiao-Jun Lin, Li Xu, Bo-Kang Cui, Jun Wang, Guo-He Lin, Ze-Yu Shuang, Yi-Ze Mao, Xin Huang, Jing-Ping Yun, Jie-Tian Jin, Sheng-Ping Li, Chen, Jian-Lin, Lao, Xiang-Ming, Lin, Xiao-Jun, Xu, Li, Cui, Bo-Kang, Wang, Jun, and Lin, Guo-He

Published
2016
Full Text
View/download PDF

37. Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies.

Author

Wang BC, Lin GH, Kuang BH, and Cao RB

Subjects
Humans, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prospective Studies, Thyroid Carcinoma, Anaplastic drug therapy, Thyroid Carcinoma, Anaplastic pathology, Thyroid Neoplasms drug therapy, Thyroid Neoplasms pathology, Thyroid Neoplasms mortality
Abstract

Background: For patients with anaplastic thyroid cancer (ATC) without mutational driver genes, chemotherapy is suggested to be the first-line treatment option. However, the benefits of chemotherapy in treating ATC are limited. In this analysis, we collected the prospective data reported since 2010 to analyze the emerging chemotherapy-based treatments in ATC comprehensively., Methods: For this updated analysis, we searched PubMed (MEDLINE), Web of Science, Embase, and Cochrane CENTRAL databases from 1 January 2010 to 7 February 2024 for prospective clinical studies that contained chemotherapy-based treatments. This analysis was done to pool overall survival (OS), progression-free survival (PFS), objective response rates (ORRs), disease control rates (DCRs), and grade 3 or worse treatment-related adverse events (TRAEs)., Results: Six prospective clinical trials with 232 patients were included. Chemotherapy was commonly combined with targeted therapy or radiotherapy. The pooled median OS was 6.0 months (95% CI 4.1-9.7), and the median PFS was 3.2 months (95% CI 1.9-6.0) in patients with ATC who received chemotherapy-based strategies. The integrated ORR and DCR were 21% (95% CI 15%-27%) and 64% (95% CI 55%-72%), respectively. Regarding the grade 3 or worse TRAE, the pooled incidence was 68% (95% CI 47%-86%)., Conclusion: Although the emerging chemotherapy-based treatments showed antitumor activity in patients with ATC, these strategies failed to prolong the survival time substantially. More practical, safe, and novel therapeutic regimens for patients with ATC warrant further investigations., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Wang, Lin, Kuang and Cao.)

Published
2024
Full Text
View/download PDF

38. Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies.

Author

Kuang BH, Zhang WX, Lin GH, Fu C, Cao RB, and Wang BC

Subjects
Humans, Retrospective Studies, Tyrosine Kinase Inhibitors, Prospective Studies, Thyroid Carcinoma, Anaplastic drug therapy, Thyroid Neoplasms drug therapy, Imidazoles, Oximes, Phenylurea Compounds, Quinolines
Abstract

Background: Tyrosine kinase inhibitors (TKIs) contribute to the treatment of patients with anaplastic thyroid cancer (ATC). Although prospective clinical studies of TKIs exhibit limited efficacy, whether ATC patients benefit from TKI treatment in real-world clinical practice may enlighten future explorations. Therefore, we conducted this effective analysis based on real-world retrospective studies to illustrate the efficacy of TKI treatment in ATC patients., Methods: We systematically searched the online databases on September 03, 2023. Survival curves were collected and reconstructed to summarize the pooled curves. Responses were analyzed by using the "meta" package. The primary endpoints were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR)., Results: 12 studies involving 227 patients were enrolled in the study. Therapeutic strategies included: anlotinib, lenvatinib, dabrafenib plus trametinib, vemurafenib, pembrolizumab plus dabrafenib and trametinib, pembrolizumab plus lenvatinib, pembrolizumab plus trametinib, and sorafenib. The pooled median OS and PFS were 6.37 months (95% CI 4.19-10.33) and 5.50 months (95% CI 2.17-12.03). The integrated ORR and DCR were 32% (95% CI 23%-41%) and 40% (95% CI 12%-74%)., Conclusion: In real-world clinical practice, ATC patients could benefit from TKI therapy. In future studies, more basic experiments and clinical explorations are needed to enhance the effects of TKIs in the treatment of patients with ATC., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Kuang, Zhang, Lin, Fu, Cao and Wang.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results